Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Mayo Clinic performs first US implant of Mitroflow Aortic Pericardial Heart Valve

Sorin : 06 December, 2007  (New Product)
The Sorin Group has completed the first commercial implant of the Mitroflow Aortic Pericardial Heart Valve in the USA, performed by the Cardiovascular Surgery Division at Mayo Clinic in Rochester, Minnesota, USA.
Designed to provide superior haemodynamic performance and ease of implant, the Mitroflow valve received FDA approval in October 2007 and is now available to cardiac surgeons and their patients in the USA.

“With its unmatched haemodynamic performance, ease of Implant and proven durability over 20 years, Sorin Group is pleased that the Mitroflow valve is now available to US surgeons and thousands of patients eligible for aortic valve replacement,” said Stefano Di Lullo, president, Cardiac Surgery Division, Sorin Group. “And we're excited to have our first Implant performed by the prestigious surgical team at the Mayo Clinic.”

The first US Mitroflow Implant was successfully performed by Rakesh M Suri, MD, Assistant Professor of Cardiac Surgery, Cardiovascular Surgery division, Mayo Clinic, Rochester, Minnesota, USA. Suri said the new valve adds to the tools available for aortic valve Implant procedures, and the search for a biological valve prosthesis with durability equal to or better than those existing on the market, with lower gradients, is a sought after goal for all patients.

Introduced in Europe in 1982, the Mitroflow valve is a testament to Sorin Group's experience with bovine pericardium, from tissue harvesting to proprietary design solutions and high technology processes. Because the pericardium is mounted on the outside of the stent, it allows for maximum valve opening and optimum blood flow.

The Mitroflow bioprosthesis offers surgeons the option, based on patient anatomy, of a supra-annular or an intra-annular valve placement designed to reduce the risk of patient-prosthesis mismatch and enhance hemodynamic performance. The streamlined sewing cuff design has shown that the valve is easy to suture, conformable to the native annulus, and adaptable to difficult anatomies.

The Mitroflow Aortic Pericardial Heart Valve will be distributed in the USA by CarboMedics, one of Sorin Group's US subsidiaries.

Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo